Specified serotype • Defined repeat boundaries • Structure-assigned research fragments
BOC Sciences supports custom bacterial capsular oligosaccharide synthesis for projects requiring a specified serotype repeat unit, a defined multi-repeat sequence, or a selected fragment. The project begins with the verified carbohydrate structure and fixes repeat boundaries, linkages, substitutions, and terminal chemistry. Synthesis and analytical documentation address the agreed oligosaccharide rather than treating a bacterial species name as a complete target definition.
Abstract repeat-boundary schematic. A, B, and C label positions in a hypothetical repeat, not assigned sugars or a bacterial serotype. Actual projects specify the complete sequence, inter-repeat bonds, native substitutions, and both fragment ends.Structure-first project review
Custom glycan synthesis
Capsular polysaccharides differ between species and serotypes and may contain branching, rare sugars, uronic acids, phosphate bridges, or other substitutions. A repeat unit is a structural description; the isolated molecule also needs defined ends. The requested fragment is therefore drawn in full, including where it starts and stops relative to the polymer repeat and which native features are retained.
A single-repeat request identifies the species, capsular serotype, complete sequence, and chosen terminal boundary. Linkage positions, anomeric configurations, sugar stereochemistry, and non-sugar components are included. A serotype label without a verified structure is the starting point for target clarification, not a sufficient chemical specification.
Projects can assess discrete repeat oligomers or shorter fragments selected for a research comparison. The exact residues and bonds retained at each end are stated, including whether a fragment spans the junction between two repeats. Equal residue counts can represent different boundary choices, so a repeat number does not replace the full molecular drawing.
Where relevant to the selected capsule, a series can compare a defined O-acetyl group, phosphate connection, terminal cap, or another explicitly assigned feature. Occupancy and position are part of the target. A de-O-acetylated or otherwise simplified model can be useful, but it is identified as that derivative rather than as an unchanged native fragment.
An aminoalkyl or other suitable arm can be reviewed for array attachment or glycoconjugate research. Its connection to the oligosaccharide and final functional group are specified alongside the capsular sequence. A completed protein conjugate, with loading and free-glycan analysis, is a separate product scope.

Project schematic
A finite capsular fragment is defined by serotype, sequence, repeat boundaries, substitutions, and both ends.Target-specific route selection
Capsular target review connects the published repeat with the finite molecule to be made. Route selection then addresses the specific sugar stereochemistry, inter-repeat connections, and native substitutions that the fragment contains. Different capsules need different building blocks and protection strategies; a successful route to one serotype does not establish access to every related structure.
The species, capsular serotype, source structure, and any updated assignment are reviewed together. A capsule structure is not inferred from an O-antigen, another surface glycan, or a closely related serotype. If the supplied drawing and reference disagree, the target must be resolved before a definitive synthesis scope can be set.
The chosen start and end residues can expose a different epitope from another fragment of the same polymer. Phosphate bridges, O-acetyl groups, pyruvyl substitutions, or other features are retained only as specified and are considered for stability during synthesis and analysis. A defined change remains visible in the product name and drawing.
A reducing-end arm supports later attachment but can change the local presentation relative to a native chain. For a length or boundary series, the handle is kept consistent where practical. The glycan target, carrier conjugation, and biological evaluation are scoped as distinct stages with their own acceptance criteria.
Structure specification
The most useful fragment is determined by the research comparison rather than by a universal minimum length. The choices below identify the structural information needed and the limits of the conclusions a supplied oligosaccharide can support.
| Design choice | Information required | Example comparison | Interpretation boundary |
|---|---|---|---|
| Complete repeat unit | Species, serotype, sequence, branch map, and selected terminal boundary | A drawn repeat-unit molecule versus a longer related fragment | One repeat is not automatically the minimal binding or protective epitope |
| Repeat number | Exact oligomer sequence and all junctions | A discrete one-repeat and two-repeat pair with aligned terminal chemistry | A repeat count alone does not define residue count for every capsule |
| Fragment boundary | Start/stop residues and inter-repeat connections retained | Equal-length fragments shifted across a repeat junction | Equal length or composition does not establish an identical epitope |
| Native substitution | Position, chemistry, and occupancy of the selected feature | Explicitly O-acetylated versus de-O-acetylated derivative where relevant | Removing a native feature creates a defined model, not an unchanged native antigen |
| Linker and display | Attachment site, anomer, arm, and optional carrier | Matched handle-bearing glycans with linker or carrier background controls | Free-glycan identity does not establish conjugate loading or immune performance |
Broader antigen and derivative requests can be connected to our Specialized Glycan Synthesis Services.
Structure-to-data consistency
The delivery package connects a sample to the exact finite structure requested. Carbohydrate sequence, native substitutions, terminal groups, and purity are assessed with suitable complementary methods. A synthetic fragment that matches a known capsular motif is a defined research material; its chemical identity does not by itself establish serotyping performance, immunogenicity, or protection.
Identity
Appropriate NMR and complementary analysis address sugar identity, glycosidic connections, anomeric configurations, branches, and inter-repeat bonds. Whole-molecule MS supports composition and fragment size. Equal mass or a serotype name alone does not establish every linkage or boundary.
Integrity
The evidence plan includes requested O-acetylation, phosphate connections, or other non-sugar features. Position and occupancy are considered separately from total content. Method conditions are reviewed for potential loss or alteration so that an analytical artifact is not confused with the intended product structure.
Derivative
Both glycan ends, any cap, and the entire appended arm appear in the product drawing. The report identifies the final group and protection state. If a carrier product is separately included, additional analysis addresses loading, free material, and the attributes of that completed construct.
Purity
A suitable separation method and structural measurements assess relevant truncated, incompletely modified, or other related species. The reported purity states its method and detection basis. A discrete synthesized fragment is distinguished from a native polysaccharide preparation or a distribution of depolymerized chains.
Research and method development
Chemically defined fragments provide controlled inputs for comparing sequence, boundary, length, and presentation. The material set is selected around the recognition or analytical question and the relevant serotype structure.
Compare defined lengths, repeat-junction boundaries, or substitution states in binding research. The experiments determine which features matter in that system. Synthesis does not identify a protective epitope or establish cross-reactivity across serotypes without corresponding data.
Provide a specified linker-bearing fragment for carrier coupling or research arrays. The completed conjugate requires its own composition and loading records, while immune response and protective activity remain separate study outcomes. A free glycan is not reported as a finished vaccine.
Use characterized fragment and isomer controls to develop NMR, chromatographic, MS, or binding-based research workflows. The relationship to the source capsule is documented explicitly. Suitability for a diagnostic or quantitative method requires separate validation for that use.
A defined research project
The inquiry stage resolves the serotype and finite fragment before route and evidence requirements are agreed. This is particularly useful when a familiar capsule name has been used for several different repeat boundaries or modified research derivatives.
Project brief
Send the species and capsular serotype, source structure and reference, fully drawn fragment boundaries, substitutions, linker or end cap, desired controls, quantity, and analytical requirements.

Associate the species and serotype with the supplied structural reference. Resolve linkage, sugar stereochemistry, repeat-junction, or substitution ambiguities in the proposed target.

Draw each full repeat oligomer, truncated sequence, boundary variant, or modification control. State both ends and keep presentation variables aligned where the comparison requires it.

Assess building-block access, stereochemical and substitution requirements, likely related products, and analysis for the distinguishing features. Specify any separate carrier or assay work.

Implement the selected synthetic sequence and isolate the finite targets. Check requested native features and final handles against the agreed structural and purity scope.

Provide sample identifiers, serotype-related sequence and source mapping, fragment boundaries, final derivative, and agreed analytical data. Report each member and control with its own identity.
Project advantages
BOC Sciences connects the capsule reference with a precise synthetic fragment and its intended downstream format. The project is organized around the structural distinctions that make the material useful for research.
The species, serotype, repeat structure, and finite endpoints stay linked, reducing ambiguity from short capsule names or shorthand repeat counts.
Length, boundary, and substitution controls can be selected deliberately, with changes documented rather than hidden within a general antigen label.
Labile or unusual substituents are considered in route planning and analysis, and intentional simplified models are identified explicitly.
The linker is selected with the intended attachment step in mind, while carrier construction and biological evaluation retain their own specifications.
One connected glycan platform
Related insights
Explore supporting information on structure definition, synthesis, and purification for your glycan research project.
Frequently asked questions
Answers to common questions about structural scope, analytical evidence, and custom synthesis requests.
Not by itself. Provide the verified repeat structure and the exact finite fragment, including linkages, sugar stereochemistry, substitutions, and both ends. A species may have multiple structurally distinct capsules, and a repeat name does not identify every possible truncated derivative.
A repeat unit describes a repeating region of the polymer. A finite molecule also has a chosen start, stop, and terminal chemistry. A fragment can contain one or more repeats, a truncated repeat, or a sequence spanning a repeat junction; the full drawing distinguishes them.
They can start at different positions within the repeat and therefore retain different terminal residues or junctions. Branching, linkage positions, and substitutions can also differ. Equal residue count or intact mass does not establish an identical molecular epitope.
A specifically positioned and occupied feature can be reviewed when it is part of the selected capsular structure. Its chemistry and analytical requirements must be included in the target. A deliberately deacetylated or otherwise simplified fragment is defined as that model rather than treated as an unchanged native structure.
Only if explicitly commissioned as a separate construct scope. A linker-equipped oligosaccharide is an input for coupling. Carrier identity, attachment, loading, residual free material, and biological evaluation require their own specifications and records.
No. The service supplies the agreed chemical structure and analytical documentation. Binding specificity, assay performance, immunogenicity, cross-reactivity, and protective effects require separate evidence for the actual material and experimental system.
Define the molecule your study needs
Share the capsular serotype reference and the exact fragment your research needs with BOC Sciences. We can review the repeat boundary, native substitutions, coupling format, comparison materials, and characterization scope for a defined synthetic oligosaccharide.
Contact BOC Sciences to discuss the target structure, proposed analytical package, and project-specific specifications. Materials are intended for research use.